SCHEMBL14629670

SCHEMBL14629670

N=C(c1ccc(C(=O)Nc2ccccc2C(=O)Nc2ccc(CI)cc2)c(F)c1)N1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 11/20 0.47
BCL3 P20749 1/20 0.45
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MCL1 Q07820 1/20 0.43
USP2 O75604 1/20 0.42
GLA P06280 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14629669 0.97 F10 (0.47) F10BCL3ALDH1A1KMT2AHPGD
SCHEMBL14632284 0.90 NPC1 (0.49) F10NPC1RAB9AMAPT
SCHEMBL14629750 0.89 F10 (0.59) F10KMT2ASMN1; SMN2NR1H4
SCHEMBL10178765 0.88 F10 (0.61) F10ALDH1A1KMT2ANPC1RAB9A
SCHEMBL13348731 0.88 F10 (0.49) F10BCL3ALDH1A1KMT2AHPGD
SCHEMBL14632283 0.87 NPC1 (0.45) F10NPC1RAB9AMAPTL3MBTL1
SCHEMBL14629783 0.87 F10 (0.61) F10
SCHEMBL10179742 0.87 F10 (0.60) F10ALDH1A1KMT2AHPGDNPC1
SCHEMBL14629953 0.86 F10 (0.52) F10KMT2A
SCHEMBL14629948 0.86 F10 (0.58) F10NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility MILLENNIUM PHARMACEUTICALS, INC. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility F2, TFPI, PLG F10 18/4885BCL3 641/4885ALDH1A1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.